Combo Therapy Delays Progression in Lung Cancer
Adults with untreated EGFR exon 20 lung cancer saw longer progression-free survival, though overall survival is still unknown.
Updated on Nov. 6, 2026 in Cancer

Results from the Phase 3 REZILIENT3 trial show that adding zipalertinib to chemotherapy extended progression-free survival in adults with untreated EGFR exon 20 non-small cell lung cancer (NSCLC). Nearly 300 patients were randomized 1:1, and the combination arm reached 14.5 months of progression-free survival versus 8.5 months with chemotherapy alone. Data are being presented at the World Conference on Lung Cancer this fall.
Why it matters
EGFR exon 20 insertions are a less common driver of NSCLC, and for people in this group the first-line options have been limited, so a trial showing longer disease control without progression is a meaningful signal for treatment planning. The design follows the established approach of adding a targeted agent to chemotherapy, which makes the result easier to place within current practice. Overall survival data remain immature, so the benefit on lifespan is not yet established.
This Phase 3 randomized trial enrolled nearly 300 patients with untreated EGFR exon 20 NSCLC, randomized 1:1 to zipalertinib plus chemotherapy or chemotherapy alone, and included patients with untreated brain metastases up to 2 cm. The combination extended progression-free survival to 14.5 months versus 8.5 months (hazard ratio 0.5), but overall survival data remain immature.
The players
U.S. Food and Drug Administration
The FDA is the U.S. agency that reviews and approves new drugs, including targeted cancer therapies such as those used in lung cancer.
World Conference on Lung Cancer
The World Conference on Lung Cancer is the international meeting of the International Association for the Study of Lung Cancer where major NSCLC research is presented.
The details
Zipalertinib is a targeted therapy designed to block the abnormal EGFR signaling driven by exon 20 insertions, and in this trial it was given alongside carboplatin and pemetrexed. Patients who progressed on chemotherapy were allowed to cross over to zipalertinib alone, and 64% did so. The most common side effects with the combination were anemia and thrombocytopenia, many of them grade 3 or higher, and these clustered in the first four treatment cycles when all three drugs were given together. Pneumonitis, a lung inflammation, occurred in 5.7% of treated patients.
Timeline
Phase 3 REZILIENT3 data are scheduled for presentation at the World Conference on Lung Cancer this fall.
A decision on the zipalertinib monotherapy new drug application is expected within the next couple of months.
Health Landscape
Targeted EGFR therapy transformed treatment for lung cancer driven by common EGFR mutations, but exon 20 insertions have historically been harder to treat with those drugs. This Phase 3 result adds to a growing set of trials testing targeted agents for that less responsive subgroup.
If you or someone you know has been diagnosed with EGFR exon 20 NSCLC, this trial is worth discussing with your oncologist, especially regarding first-line treatment options. Ask your care team about the side effect profile, including blood count monitoring and the risk of lung inflammation, before making any treatment decisions.
The takeaway
Adding a targeted drug to chemotherapy delayed disease progression in this trial, though longer-term survival data are still pending. For anyone with EGFR exon 20 lung cancer, a conversation with a specialist about current and emerging options is the most useful next step.
What happens next
The FDA decision on the zipalertinib monotherapy new drug application is expected within the next couple of months, and full REZILIENT3 data will be presented at the World Conference on Lung Cancer this fall.
Further reading
For more on how these treatments are being studied, explore our Cancer coverage.
Source note: This article includes information reported by Ajmc.


